New Alzheimer’s drug appears to slow cognitive decline but is ‘not a breakthrough’
December 09, 2022 at 10:50 AM EST
Lecanemab, the drug being tested by Biogen and Eisai, was found to have a modest benefit to patients in a Phase 3 study.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
San Anselmo | San Anselmo News | San Anselmo Travel | Restaurants | Nightlife | Things To Do | Shopping | Calendar | Directory | Real Estate | Blog | More
|